Coal prices hit a record as utilities burn the fuel to fill in gaps left by reduced gas supply from Russia
Companies touting psilocybin as a cure for depression are having to prove they have a viable business model
They hope the magic mushroom sector can avoid the mistakes made when marijuana became legal
A French court has ruled that families of children who suffered side effects from the epilepsy medicine Depakine can join in a class-action lawsuit against drugmaker Sanofi.
The company should have warned of the risk of birth defects for pregnant women taking the medicine as early as 1984, a Paris court said on Wednesday. Instead it only took those steps in 2003, it said, calling the product that was sold for decades “defective”.
Depakine is a powerful anti-epileptic drug that’s on the World Health Organization’s list of essential medicines, but it has been blamed for neuro-development problems in tens of thousands of children in a long-running court case in Sanofi’s home market. A class-action lawsuit would be a legal first in France, according to Agence France-Presse.
Sanofi said it will appeal the decision. The drugmaker said it has co-operated with authorities and hasn’t been found responsible in any legal proceedings involving Depakine. The stock rose less than 1% in Paris trading.
The class-action lawsuit may also be directed at Sanofi’s insurer, a unit of Allianz, the court said.
More stories like this are available on Bloomberg.com
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.